Related Experiment Video
Updated: Nov 9, 2025

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
Published on: August 16, 2024
Evaluation of the Potential Effect of Iptakalim Hydrochloride on the QT Interval in Single- and
Nan Bai1, Jin Wang1, Haoyue Che1
1Chinese People's Liberation Army General Hospital, Medicine Clinical Research Center, Beijing, China.
Insights
Iptakalim hydrochloride (ITKL) did not prolong the QT interval in healthy subjects. This study assessed cardiac repolarization effects of ITKL, a hypertension drug, finding no significant QTc interval changes at therapeutic doses.
Area of Science:
- Pharmacology
- Cardiology
- Clinical Trials
Background:
- Cardiotoxicity is a major reason for drug withdrawal.
- QT interval prolongation is a key indicator of drug-induced cardiotoxicity.
- Assessing cardiac repolarization risk is vital for new antihypertensive drugs like Iptakalim hydrochloride (ITKL).
Purpose of the Study:
- To evaluate the effect of Iptakalim hydrochloride (ITKL) on the corrected QT (QTc) interval.
- To investigate the correlation between ITKL plasma concentration and QTc interval changes.
- To determine the cardiac safety profile of ITKL regarding repolarization in healthy subjects.
Main Methods:
- A randomized, double-blind, placebo-controlled study.
- Single and multiple oral doses of ITKL (5-20 mg) administered to 83 healthy subjects.
- Electrocardiograms (ECGs) and blood samples collected to monitor QTc interval and ITKL levels.
Main Results:
- No significant prolongation of the QTc interval was observed at any tested plasma level of ITKL.
- The maximum observed ΔΔQTcF effect was below the exclusion threshold of 10 milliseconds.
- Even at twice the therapeutic dose (20 mg), ITKL did not affect QTc interval.
Conclusions:
- Iptakalim hydrochloride (ITKL) does not prolong the QT interval in healthy subjects within the therapeutic dose range.
- ITKL demonstrates a favorable cardiac safety profile concerning repolarization.
- Further clinical evaluation can proceed with confidence in ITKL's cardiac safety.
Abstract:
Cardiotoxicity has been one of the most common causes of withdrawal of drugs from the market, and prolongation of the QT interval is one of the manifestations of drug cardiotoxicity. Iptakalim hydrochloride (ITKL) is a selective ATP-sensitive potassium channel opener used to treat hypertension. It is crucial to assess the risk of cardiac repolarization of ITKL in clinical trials. This study was conducted to determine the effect of ITKL on corrected QT (QTc) interval. A randomized, double-blind, placebo-controlled single- and multidose regimen was carried out to investigate the QTc and ITKL concentration correlation. ITKL was administered at doses of 5, 10, 15, and 20 mg with single oral administration and 10 and 20 mg with multiple oral administration, along with placebo, in 83 healthy subjects. Electrocardiograms (ECGs) and blood samples were collected on a preset time schedule. A ΔΔQTcF effect above 10 milliseconds was excluded at all observed plasma levels. Among them, the highest dose was 20 mg, which is twice the therapeutic dose. We concluded that ITKL did not prolong the QT interval in healthy subjects within the therapeutic dose. Retrospectively registered: The study was registered at Chinese Clinical Trial Registry with registration number ChiCTR1800014466.
More Related Videos
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Time Course of Drug Effect
Dosage Interval and Administration Route: Determination Methods
One-Compartment Model: IV Infusion
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...

